Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression. Stehle T, Grimbert P, Remy P, Moktefi A, et al. Kidney Int 2022;101:416-418.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Stehle T, Grimbert P, Remy P, Moktefi A, et al. Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression. Kidney Int 2022;101:416-418.
PMID: 35065692